These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 31233281)

  • 1. Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate.
    Fleischmann R; Takeuchi T; Schiff M; Schlichting D; Xie L; Issa M; Stoykov I; Lisse J; Martinez-Osuna P; Rooney T; Zerbini CAF
    Arthritis Care Res (Hoboken); 2020 Aug; 72(8):1112-1121. PubMed ID: 31233281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.
    van der Heijde D; Durez P; Schett G; Naredo E; Østergaard M; Meszaros G; De Leonardis F; de la Torre I; López-Romero P; Schlichting D; Nantz E; Fleischmann R
    Clin Rheumatol; 2018 Sep; 37(9):2381-2390. PubMed ID: 30078086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
    Fleischmann R; Schiff M; van der Heijde D; Ramos-Remus C; Spindler A; Stanislav M; Zerbini CA; Gurbuz S; Dickson C; de Bono S; Schlichting D; Beattie S; Kuo WL; Rooney T; Macias W; Takeuchi T
    Arthritis Rheumatol; 2017 Mar; 69(3):506-517. PubMed ID: 27723271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study.
    Smolen JS; Xie L; Jia B; Taylor PC; Burmester G; Tanaka Y; Elias A; Cardoso A; Ortmann R; Walls C; Dougados M
    Rheumatology (Oxford); 2021 May; 60(5):2256-2266. PubMed ID: 33200220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
    Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.
    van der Heijde D; Kartman CE; Xie L; Beattie S; Schlichting D; Mo D; Durez P; Tanaka Y; Fleischmann R
    J Rheumatol; 2022 Feb; 49(2):133-141. PubMed ID: 34526397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
    Lopez-Romero P; de la Torre I; Haladyj E; Aletaha D; Smolen JS
    Ann Rheum Dis; 2022 May; 81(5):622-631. PubMed ID: 35193872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study.
    Caporali R; Taylor PC; Aletaha D; Sanmartí R; Takeuchi T; Mo D; Haladyj E; Bello N; Zaremba-Pechmann L; Fang Y; Dougados M
    Rheumatology (Oxford); 2024 Oct; 63(10):2799-2809. PubMed ID: 38258434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
    Tanaka Y; Fautrel B; Keystone EC; Ortmann RA; Xie L; Zhu B; Issa M; Patel H; Gaich CL; de Bono S; Rooney TP; Taylor PC
    Ann Rheum Dis; 2019 Jul; 78(7):890-898. PubMed ID: 31040122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy.
    Taylor PC; Alten R; Álvaro Gracia JM; Kaneko Y; Walls C; Quebe A; Jia B; Bello N; Terres JR; Fleischmann R
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35264432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.
    Emery P; Tanaka Y; Cardillo T; Schlichting D; Rooney T; Beattie S; Helt C; Smolen JS
    Arthritis Res Ther; 2020 May; 22(1):115. PubMed ID: 32414425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
    Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
    J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
    Keystone EC; Taylor PC; Drescher E; Schlichting DE; Beattie SD; Berclaz PY; Lee CH; Fidelus-Gort RK; Luchi ME; Rooney TP; Macias WL; Genovese MC
    Ann Rheum Dis; 2015 Feb; 74(2):333-40. PubMed ID: 25431052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.
    Keystone EC; Genovese MC; Schlichting DE; de la Torre I; Beattie SD; Rooney TP; Taylor PC
    J Rheumatol; 2018 Jan; 45(1):14-21. PubMed ID: 28811354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
    Emery P; Durez P; Hueber AJ; de la Torre I; Larsson E; Holzkämper T; Tanaka Y
    Arthritis Res Ther; 2021 Jan; 23(1):3. PubMed ID: 33397481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.
    Kavanaugh A; van Vollenhoven RF; Fleischmann R; Emery P; Sainsbury I; Florentinus S; Chen S; Guérette B; Kupper H; Smolen JS
    Ann Rheum Dis; 2018 Feb; 77(2):289-292. PubMed ID: 29146743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baricitinib: A Review in Rheumatoid Arthritis.
    Al-Salama ZT; Scott LJ
    Drugs; 2018 May; 78(7):761-772. PubMed ID: 29687421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.
    Kremer JM; Rigby W; Singer NG; Birchwood C; Gill D; Reiss W; Pei J; Michalska M
    Arthritis Rheumatol; 2018 Aug; 70(8):1200-1208. PubMed ID: 29575803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
    Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.